Literature DB >> 12738709

Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice.

Carlos L Arteaga1, Jose Baselga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12738709

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  15 in total

1.  Phenotypic variation resulting from a deficiency of epidermal growth factor receptor in mice is caused by extensive genetic heterogeneity that can be genetically and molecularly partitioned.

Authors:  Karen E Strunk; Vicky Amann; David W Threadgill
Journal:  Genetics       Date:  2004-08       Impact factor: 4.562

2.  Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells in human renal cell carcinoma is a primary target for therapy by tyrosine kinase inhibitors.

Authors:  Cheryl H Baker; Maria S Pino; Isaiah J Fidler
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

Review 3.  Transcatheter intraarterial therapies: rationale and overview.

Authors:  Robert J Lewandowski; Jean-Francois Geschwind; Eleni Liapi; Riad Salem
Journal:  Radiology       Date:  2011-06       Impact factor: 11.105

Review 4.  Panitumumab: in the treatment of metastatic colorectal cancer.

Authors:  Sheridan M Hoy; Antona J Wagstaff
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 5.  p27 deregulation in breast cancer: prognostic significance and implications for therapy.

Authors:  A Alkarain; R Jordan; J Slingerland
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

Review 6.  Turning laboratory findings into therapy: a marathon goal that has to be reached.

Authors:  Beatrix Kotlan; David F Stroncek; Francesco M Marincola
Journal:  Pol Arch Med Wewn       Date:  2009-09

7.  Potent cardioprotective effect of the 4-anilinoquinazoline derivative PD153035: involvement of mitochondrial K(ATP) channel activation.

Authors:  Renata A Cavalheiro; Rodrigo M Marin; Silvana A Rocco; Fernanda M Cerqueira; Camille C Caldeira da Silva; Roberto Rittner; Alicia J Kowaltowski; Anibal E Vercesi; Kleber G Franchini; Roger F Castilho
Journal:  PLoS One       Date:  2010-05-17       Impact factor: 3.240

8.  Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas.

Authors:  Elzbieta Stankiewicz; David M Prowse; Mansum Ng; Jack Cuzick; David Mesher; Frances Hiscock; Yong-Jie Lu; Nicholas Watkin; Catherine Corbishley; Wayne Lam; Daniel M Berney
Journal:  PLoS One       Date:  2011-03-02       Impact factor: 3.240

9.  Quantification of epidermal growth factor receptor expression level and binding kinetics on cell surfaces by surface plasmon resonance imaging.

Authors:  Fenni Zhang; Shaopeng Wang; Linliang Yin; Yunze Yang; Yan Guan; Wei Wang; Han Xu; Nongjian Tao
Journal:  Anal Chem       Date:  2015-10-06       Impact factor: 6.986

10.  Composites of Nucleic Acids and Boron Clusters (C2B10H12) as Functional Nanoparticles for Downregulation of EGFR Oncogene in Cancer Cells.

Authors:  Damian Kaniowski; Katarzyna Ebenryter-Olbińska; Katarzyna Kulik; Justyna Suwara; Wojciech Cypryk; Agata Jakóbik-Kolon; Zbigniew Leśnikowski; Barbara Nawrot
Journal:  Int J Mol Sci       Date:  2021-05-04       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.